Answers are grounded in this paper and cite their sources.
In an accompanying editorial, Krell and Stebbing 2 recommended that the same stage-stratified approach, yielding good outcomeswhenappliedasa(nonrandomized)strategyatasinglesiteina high-resource setting, be adopted globally, and that if cost and chemotherapy-related infrastructural barriers could be overcome, pegylated liposomal doxorubicin should be made available for all patients with advanced-stage KS in sub-Saharan Africa (SSA), where the world’s burden of HIV-associated KS is concentrated. As investigatorsinvolvedinstudyingHIV-associatedKSinSSA,webelievethat morecomplexissuesmustberigorouslyaddressedbeforerecommendations for optimal treatment in this setting can be made. The editorial 2 does not consider significant differences between patientsinresource-richandresource-limitedsettingsthatmayinflu
No takes yet. Share an insight, caveat, or question.
Krown et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: